Matthias A. Karajannis

17.1k total citations
85 papers, 2.8k citations indexed

About

Matthias A. Karajannis is a scholar working on Genetics, Neurology and Molecular Biology. According to data from OpenAlex, Matthias A. Karajannis has authored 85 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 35 papers in Neurology and 28 papers in Molecular Biology. Recurrent topics in Matthias A. Karajannis's work include Glioma Diagnosis and Treatment (40 papers), Meningioma and schwannoma management (20 papers) and Neurofibromatosis and Schwannoma Cases (20 papers). Matthias A. Karajannis is often cited by papers focused on Glioma Diagnosis and Treatment (40 papers), Meningioma and schwannoma management (20 papers) and Neurofibromatosis and Schwannoma Cases (20 papers). Matthias A. Karajannis collaborates with scholars based in United States, Germany and United Kingdom. Matthias A. Karajannis's co-authors include Jeffrey C. Allen, David Zagzag, Filippo G. Giancotti, Matija Snuderl, Jonathan M. Cooper, Wei Li, Geneviève Legault, Marc Ladanyi, Charles G. Eberhart and Jeffrey H. Wisoff and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Matthias A. Karajannis

80 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthias A. Karajannis United States 29 1.1k 1.1k 1.1k 602 404 85 2.8k
David Meyronet France 27 609 0.5× 1.0k 0.9× 878 0.8× 394 0.7× 395 1.0× 115 2.6k
Marco Gessi Italy 31 702 0.6× 1.4k 1.2× 1.1k 1.1× 434 0.7× 523 1.3× 138 3.2k
Ho Jun Seol South Korea 28 805 0.7× 877 0.8× 621 0.6× 936 1.6× 607 1.5× 148 3.1k
Michael H. Handler United States 29 458 0.4× 1.0k 0.9× 1.1k 1.1× 475 0.8× 328 0.8× 58 2.4k
André O. von Bueren Germany 28 595 0.5× 1.4k 1.3× 1.2k 1.1× 343 0.6× 464 1.1× 111 2.3k
Juan A. Rey Spain 36 1.1k 0.9× 1.4k 1.3× 2.1k 1.9× 918 1.5× 489 1.2× 171 3.9k
Brent A. Orr United States 34 537 0.5× 1.2k 1.1× 1.8k 1.7× 261 0.4× 389 1.0× 125 3.1k
Andrew M. Donson United States 35 552 0.5× 1.2k 1.1× 1.7k 1.6× 456 0.8× 451 1.1× 112 3.0k
Jason Fangusaro United States 28 904 0.8× 1.4k 1.3× 865 0.8× 314 0.5× 416 1.0× 102 2.5k
Naoki Shinojima Japan 26 363 0.3× 1.3k 1.2× 1.3k 1.2× 720 1.2× 283 0.7× 80 3.0k

Countries citing papers authored by Matthias A. Karajannis

Since Specialization
Citations

This map shows the geographic impact of Matthias A. Karajannis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias A. Karajannis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias A. Karajannis more than expected).

Fields of papers citing papers by Matthias A. Karajannis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias A. Karajannis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias A. Karajannis. The network helps show where Matthias A. Karajannis may publish in the future.

Co-authorship network of co-authors of Matthias A. Karajannis

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias A. Karajannis. A scholar is included among the top collaborators of Matthias A. Karajannis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias A. Karajannis. Matthias A. Karajannis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tringale, Kathryn R., Ira J. Dunkel, Sameer Farouk Sait, et al.. (2024). Hypofractionated re‐irradiation for diffuse intrinsic pontine glioma. Pediatric Blood & Cancer. 71(5). e30929–e30929. 3 indexed citations
2.
Dinh, Christine T., Julianne Huegel, Alejandra M. Petrilli, et al.. (2023). Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells. Molecular Cancer Therapeutics. 22(11). 1280–1289. 1 indexed citations
3.
Plotkin, Scott R., Jeffrey C. Allen, Girish Dhall, et al.. (2023). Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology. 25(8). 1498–1506. 12 indexed citations
4.
Fuller, Christine, Olivia Campagne, Tong Lin, et al.. (2021). A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research. 27(9). 2442–2451. 17 indexed citations
5.
Sait, Sameer Farouk, Stephen W. Gilheeney, Tejus Bale, et al.. (2021). Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas. JCO Precision Oncology. 5(5). 876–883. 20 indexed citations
6.
Sait, Sameer Farouk, Michael F. Walsh, & Matthias A. Karajannis. (2021). Genetic syndromes predisposing to pediatric brain tumors. Neuro-Oncology Practice. 8(4). 375–390. 5 indexed citations
7.
Miller, Alexandra, Luca Szalontay, Nancy Bouvier, et al.. (2020). BIOM-56. THE INTEGRATION OF A LIQUID BIOPSY PROGRAM INTO THE CARE OF PEDIATRIC BRAIN TUMOR PATIENTS. Neuro-Oncology. 22(Supplement_2). ii13–ii14.
8.
Plotkin, Scott R., Dan G. Duda, Alona Muzikansky, et al.. (2019). Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. Journal of Clinical Oncology. 37(35). 3446–3454. 74 indexed citations
9.
Sparrow, Nicklaus A., et al.. (2019). Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival. Journal of Biological Chemistry. 294(30). 11354–11368. 11 indexed citations
10.
De, Brian, Yasmin Khakoo, Mark M. Souweidane, et al.. (2018). Patterns of relapse for children with localized intracranial ependymoma. Journal of Neuro-Oncology. 138(2). 435–445. 12 indexed citations
11.
Kirches, Elmar, Felix Sahm, Christina Blücher, et al.. (2018). NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology. 20(suppl_2). i144–i145. 1 indexed citations
12.
Cooper, Jonathan M., Qingwen Xu, Lü Zhou, et al.. (2017). Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis. Molecular Cancer Therapeutics. 16(8). 1693–1704. 33 indexed citations
13.
Cooper, Benjamin T., Shaoqing Wu, Christopher Bowman, et al.. (2017). A DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. International Journal of Radiation Oncology*Biology*Physics. 99(2). E566–E566. 6 indexed citations
14.
15.
Li, Wei, Jonathan M. Cooper, Lü Zhou, et al.. (2014). Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell. 26(1). 48–60. 183 indexed citations
16.
Legault, Geneviève, Mark W. Kieran, R. Michael Scott, et al.. (2013). Recurrent Ascites in a Patient With Low-grade Astrocytoma and Ventriculo-Peritoneal Shunt Treated With the Multikinase Inhibitor Sorafenib. Journal of Pediatric Hematology/Oncology. 36(8). e533–e535. 3 indexed citations
17.
Lin, Alex Y., Fausto J. Rodríguez, Matthias A. Karajannis, et al.. (2011). BRAFAlterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549. Journal of Neuropathology & Experimental Neurology. 71(1). 66–72. 111 indexed citations
18.
Sethi, Rajni, Jeffrey C. Allen, Bernadine Donahue, et al.. (2010). Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. Journal of Neuro-Oncology. 102(1). 121–127. 47 indexed citations
19.
Narayana, A., Saroj Kunnakkat, Sharon L. Gardner, et al.. (2010). Bevacizumab in recurrent high-grade pediatric gliomas. Neuro-Oncology. 12(9). 985–990. 65 indexed citations
20.
Karajannis, Matthias A., et al.. (2000). Recurrent B‐cell non‐Hodgkin's lymphoma in two brothers with X‐linked lymphoproliferative disease without evidence for Epstein–Barr virus infection. British Journal of Haematology. 108(2). 377–382. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Meyronet Breakdown of academic impact, for papers by Marco Gessi Breakdown of academic impact, for papers by Ho Jun Seol Breakdown of academic impact, for papers by Michael H. Handler Breakdown of academic impact, for papers by André O. von Bueren Breakdown of academic impact, for papers by Juan A. Rey Breakdown of academic impact, for papers by Brent A. Orr Breakdown of academic impact, for papers by Andrew M. Donson Breakdown of academic impact, for papers by Jason Fangusaro Breakdown of academic impact, for papers by Naoki Shinojima
Rankless by CCL
2026